{"id":251497,"date":"2024-03-12T00:00:00","date_gmt":"2024-03-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidcg0054-biopharma-hiv-aids-related-neuropathy-epidemiology\/"},"modified":"2026-05-06T11:13:50","modified_gmt":"2026-05-06T11:13:50","slug":"epidcg0054-biopharma-hiv-aids-related-neuropathy-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcg0054-biopharma-hiv-aids-related-neuropathy-epidemiology-mature-markets\/","title":{"rendered":"HIV\/AIDS-Related Neuropathy &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of human immunodeficiency virus\/acquired immunodeficiency syndrome (<abbr title=\"human immunodeficiency virus\">HIV<\/abbr>\/<abbr title=\"acquired immunodeficiency syndrome\">AIDS<\/abbr>)-related neuropathy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of <abbr title=\"human immunodeficiency virus\">HIV<\/abbr>\/<abbr title=\"acquired immunodeficiency syndrome\">AIDS<\/abbr>-related neuropathy for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"human immunodeficiency virus\">HIV<\/abbr>\/<abbr title=\"acquired immunodeficiency syndrome\">AIDS<\/abbr>-related neuropathy forecast will answer the following question:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"human immunodeficiency virus\">HIV<\/abbr>\/<abbr title=\"acquired immunodeficiency syndrome\">AIDS<\/abbr>-related neuropathy over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <span class=\"abbreviation-guard\">MS<\/span> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts four <abbr title=\"human immunodeficiency virus\">HIV<\/abbr>\/<abbr title=\"acquired immunodeficiency syndrome\">AIDS<\/abbr>-related neuropathy patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Total prevalent cases of <abbr title=\"human immunodeficiency virus\">HIV<\/abbr>\/<abbr title=\"acquired immunodeficiency syndrome\">AIDS<\/abbr>-related neuropathy.<\/li>\n<li>Total prevalent cases <abbr title=\"human immunodeficiency virus\">HIV<\/abbr>\/<abbr title=\"acquired immunodeficiency syndrome\">AIDS<\/abbr>-related neuropathic pain.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"human immunodeficiency virus\">HIV<\/abbr>\/<abbr title=\"acquired immunodeficiency syndrome\">AIDS<\/abbr>-related neuropathy.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"human immunodeficiency virus\">HIV<\/abbr>\/<abbr title=\"acquired immunodeficiency syndrome\">AIDS<\/abbr>-related neuropathic pain.<\/li>\n<li>\u2026 and more (details available on request).<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251497","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-neurology","biopharma-product-epidemiology","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251497","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251497\/revisions"}],"predecessor-version":[{"id":305218,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251497\/revisions\/305218"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251497"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}